Furosemide Prices, Trend 2026: Index, Demand, Chart and Forecast

According to ChemAnalyst, The global Furosemide Prices moved upward during the second quarter of 2026, reflecting a combination of higher producer input costs, changing pharmaceutical demand, feedstock volatility, and regional supply-chain conditions. Furosemide, a widely used loop diuretic, remains an important active pharmaceutical ingredient (API) for the production of medicines used to manage fluid retention associated with conditions such as heart failure, liver disease, and certain kidney disorders.

During Q2 2026, price movements varied across major regional markets. In APAC, higher producer costs supported an increase in the Furosemide Price Index, while stable industrial activity helped maintain supply availability. In North America, stronger producer inflation and tighter global chemical supply conditions contributed to higher pricing. Meanwhile, the European market also experienced upward price pressure as energy, naphtha, and intermediate costs increased, particularly in Germany.

The combination of relatively stable pharmaceutical consumption and rising manufacturing expenses suggests that the Furosemide Price Trend will remain firm in the near term. Buyers and pharmaceutical manufacturers are therefore expected to closely monitor API production costs, chemical feedstocks, energy prices, and international trade conditions.

Furosemide Prices in APAC

The Furosemide Price Index in APAC increased quarter-over-quarter during Q2 2026, with China emerging as one of the key markets contributing to the regional upward movement. Rising producer input costs placed pressure on manufacturers, while demand conditions remained comparatively stable.

In China, Furosemide production costs increased during June 2026, with the Producer Price Index (PPI) rising 4.1% year-over-year. The increase in producer-level inflation reflected higher costs across industrial inputs and contributed to elevated manufacturing expenses for pharmaceutical intermediates and APIs.

Despite these cost pressures, the Furosemide demand outlook remained relatively stable. The unemployment rate stood at 5.0% in June 2026, indicating a comparatively stable labor environment and continued access to healthcare products. Pharmaceutical demand was therefore sufficiently resilient to prevent a significant deterioration in market activity.

India remained another important market within the APAC Furosemide supply chain. The FOB price of Furosemide settled at approximately USD 4,950/MT in June 2026. Indian producers benefited from stable industrial activity, with industrial production increasing 5.3% year-over-year in June 2026. Strong industrial performance supported manufacturing continuity and helped maintain the availability of pharmaceutical products and chemical inputs.

At the same time, India's relatively subdued consumer inflation environment helped moderate some downstream operating expenses. The Consumer Price Index (CPI) increased only 1.0% in June 2026, limiting broader inflationary pressure on non-API costs.

However, retail activity remained relatively soft, with retail sales growth at 1.0% in June 2026. This suggested that consumer-side economic momentum was restrained, creating some indirect pressure on pharmaceutical demand. Nevertheless, the essential nature of medicines containing Furosemide helped keep underlying consumption comparatively stable.

Why Did the Price of Furosemide Change in June 2026 in APAC?

Several factors contributed to the increase in Furosemide Prices in APAC during June 2026:

• Higher producer costs: China's PPI increased 4.1% year-over-year, raising manufacturing expenses.
• Stable pharmaceutical demand: Healthcare requirements continued to support Furosemide consumption despite moderate consumer spending.
• Strong industrial production in India: Industrial output grew 5.3% year-over-year, supporting stable production and supply chains.
• Low general inflation in India: CPI growth of 1.0% limited broader operating cost increases.
• Moderate retail activity: Retail sales growth of 1.0% indicated restrained consumer spending, although this had a limited effect on essential pharmaceutical demand.

Overall, APAC's Furosemide Price Trend remained upward, primarily because increasing production costs outweighed the impact of moderate demand-side pressures.

Get Real Time Online for Furosemide Prices: https://www.chemanalyst.com/Pricing-data/furosemide-1495

Furosemide Prices in North America

The Furosemide Price Index in North America also increased quarter-over-quarter in Q2 2026. The United States market experienced substantial producer cost inflation, while global chemical supply disruptions added further pressure to pharmaceutical manufacturing expenses.

In June 2026, the US Producer Price Index increased 5.5% year-over-year. This substantial increase indicates a pronounced rise in producer-level costs and contributed to higher expenses for pharmaceutical manufacturers. Since Furosemide production depends on multiple chemical intermediates and industrial inputs, increases in upstream manufacturing costs can ultimately be reflected in API pricing.

The market was also influenced by a broader increase in global chemical prices during Q2 2026. Geopolitical conflicts, crude oil price movements, and disruptions in feedstock supply affected international chemical trade flows. These developments increased procurement risks for manufacturers dependent on imported raw materials and intermediates.

Global chemical supply tightened during the quarter as geopolitical disruptions affected production and transportation routes. Longer lead times, increased freight expenses, and uncertainties surrounding material availability created additional pressure on pharmaceutical supply chains.

Despite higher costs, Furosemide demand in the United States remained stable. An upward trend in healthcare spending supported pharmaceutical consumption and helped offset some of the pressure generated by broader economic uncertainty.

Retail sales increased 6.9% year-over-year in May 2026, demonstrating relatively strong consumer activity. The US unemployment rate was also comparatively low at 4.2% in June 2026, supporting household income and healthcare affordability.

However, general inflation remained a cost concern. The US CPI increased 3.5% year-over-year in June 2026, raising expenses associated with labor, logistics, utilities, packaging, and other operational requirements throughout the pharmaceutical supply chain.

Why Did the Price of Furosemide Change in June 2026 in North America?

The main factors influencing the Furosemide Price Trend in North America included:

• PPI growth of 5.5%: Higher producer prices increased API manufacturing and raw-material costs.
• Higher global chemical prices: Crude oil and feedstock volatility raised upstream procurement expenses.
• Geopolitical disruptions: Supply-chain uncertainty affected chemical availability and international trade flows.
• Healthcare spending growth: Higher healthcare expenditure helped maintain stable demand for Furosemide.
• Strong retail sales: Retail sales growth of 6.9% supported overall economic activity and patient purchasing capacity.
• CPI inflation of 3.5%: Higher operating expenses added to the cost base for pharmaceutical producers.

Consequently, North American Furosemide Prices remained under considerable upward pressure during Q2 2026.

Furosemide Prices in Europe

The European Furosemide Price Index also increased quarter-over-quarter during Q2 2026, with Germany representing a key regional market. Higher producer prices, elevated feedstock costs, intermediate shortages, and steady pharmaceutical demand contributed to the increase.

In Germany, the PPI increased 2.2% in May 2026, indicating higher producer-level expenses across industrial sectors. These costs filtered through the pharmaceutical manufacturing chain and contributed to higher Furosemide production expenses.

One important cost factor was the movement in naphtha feedstock prices. Naphtha prices firmed in Europe during April 2026, increasing the cost pressure on chemical intermediates and other inputs used throughout the pharmaceutical manufacturing process. Higher energy expenses added another layer of pressure to production economics.

Material shortages also became increasingly relevant. In May 2026, shortages of intermediate products intensified across Germany's chemical industry. For Furosemide manufacturers, constrained availability of relevant intermediates can increase procurement costs, extend production lead times, and encourage suppliers to maintain higher quotations.

Germany's CPI increased 2.3% in June 2026, adding to operating cost pressures. Although the increase was less pronounced than producer inflation in some other markets, it still affected energy, logistics, labor, packaging, and other supporting expenses.

Demand fundamentals, however, remained favorable. Germany's aging population and increasing medical treatment requirements supported pharmaceutical consumption during Q2 2026. This provided a relatively stable demand base for medicines containing Furosemide.

Retail sales increased 1.8% in May 2026, while the unemployment rate remained stable at 3.8%. These indicators supported overall economic resilience and helped sustain access to healthcare products.

The pharmaceutical sector also experienced market expansion during Q2 2026, although contracting consumer confidence in June created some broader economic uncertainty. Meanwhile, Germany's industrial production remained unchanged at 0.0% in May 2026, and the Manufacturing Index contracted in June. These industrial indicators suggested that the wider manufacturing environment remained challenging.

Why Did the Price of Furosemide Change in June 2026 in Europe?

The principal drivers behind the European Furosemide Price Trend were:

• German PPI increased 2.2%: Higher producer costs raised pharmaceutical manufacturing expenses.
• Firm naphtha prices: Stronger feedstock costs increased the cost of chemical intermediates.
• Intermediate shortages: Tight availability increased procurement and production risks.
• CPI increased 2.3%: Broader inflation added to operational expenses.
• Growing pharmaceutical demand: An aging population and increased medical treatment supported consumption.
• Industrial-sector weakness: Flat industrial production and a contracting manufacturing index limited supply-side flexibility.

The balance between higher production costs and steady pharmaceutical demand kept the European Furosemide Price Index firm during Q2 2026.

Global Furosemide Price Trend Analysis

The Q2 2026 market demonstrates that Furosemide Prices are increasingly influenced by upstream cost conditions rather than dramatic changes in end-use pharmaceutical demand.

Across APAC, North America, and Europe, manufacturers faced higher costs for raw materials, energy, chemical intermediates, logistics, and other production inputs. These increases created a relatively broad-based upward pricing environment.

At the same time, demand remained relatively resilient because Furosemide is an established pharmaceutical ingredient used in essential healthcare applications. Consequently, demand did not decline sharply even when consumer spending indicators were mixed.

The most significant regional cost pressure was observed in the United States, where PPI increased 5.5% year-over-year in June. China also experienced notable producer inflation, while Germany faced a combination of higher producer prices, firmer naphtha costs, and intermediate shortages.

This combination suggests that procurement teams should pay particular attention to API feedstock costs, supplier inventories, energy prices, and international chemical trade flows when evaluating future Furosemide purchasing strategies.

Book A Demo for Furosemide Prices: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Furosemide

Furosemide Price Forecast

The Furosemide Price Forecast indicates that prices are likely to maintain an upward bias in the near term. Persistent increases in producer input costs are expected to remain the primary source of price pressure.

In APAC, stronger industrial production and stable pharmaceutical demand could support manufacturing activity, but rising producer costs may continue to push prices higher. India is likely to remain an important supply source, with its strong industrial growth supporting production continuity.

In North America, elevated producer inflation and global chemical-market volatility are expected to remain important factors. Any further disruption to crude oil, feedstock, or international chemical supply could increase production and logistics expenses.

Europe is also expected to experience firm pricing conditions. Continued energy-cost volatility, intermediate availability, and pharmaceutical demand associated with demographic trends could prevent a significant decline in prices.

However, the extent of future price increases will depend on the development of raw-material costs, chemical inventories, manufacturing utilization rates, freight expenses, and pharmaceutical procurement patterns.

Conclusion

The Furosemide Prices market recorded a generally firm performance during Q2 2026, with APAC, North America, and Europe all experiencing upward price pressure. The primary driver was rising production costs, supported by higher producer prices, feedstock expenses, energy costs, and tighter chemical supply conditions.

In APAC, China's PPI growth and India's strong industrial production shaped market conditions, while Furosemide FOB prices in India settled around USD 4,950/MT in June 2026. North America faced stronger producer inflation, global chemical disruptions, and higher operational expenses, while stable healthcare spending supported demand. In Europe, Germany experienced higher producer prices, firm naphtha costs, intermediate shortages, and steady pharmaceutical consumption.

Looking forward, the Furosemide Price Forecast remains cautiously bullish. Unless upstream input costs ease significantly or chemical supply conditions improve, manufacturers and buyers are likely to continue facing firm API pricing. Monitoring feedstock markets, production costs, inventory levels, geopolitical developments, and pharmaceutical demand will therefore remain essential for understanding the next phase of the global Furosemide market.

 

About Us:

Welcome to ChemAnalyst, a next–generation platform for chemical and petrochemical intelligence where innovation meets practical insight. Recognized as “Product Innovator of the Year 2023” and ranked among the “Top 100 Digital Procurement Solutions Companies,” we lead the digital transformation of the global chemical sector. Our online platform helps companies handle price volatility with structured analysis, real-time pricing, and reliable news and deal updates from across the world. Tracking over 500 chemical prices in more than 40 countries becomes simple and efficient with us.

Contact Us:

Address:

420 Lexington Avenue, Suite 300 New York, NY 10170 United States

Phone: +1 332 258 6602

Email: sales@chemanalyst.com

Website: https://www.chemanalyst.com/

LinkedIn: https://www.linkedin.com/company/chemanalyst/

Facebook: https://www.facebook.com/ChemAnalysts/

Twitter: https://x.com/chemanalysts

YouTube: https://www.youtube.com/@chemanalyst

Instagram: https://www.instagram.com/chemanalyst_